Wikipedia

Kairbaan Hodivala-Dilke

Kairbaan Hodivala-Dilke, FMedSci is an English cell biologist who has made significant contributions to the understanding of the cellular and molecular biology of the tumour microenvironment and in particular angiogenesis.[1] She is Professor of Angiogenesis and the Tumour Microenvironment and Deputy Institute Director of Barts Cancer Institute, Queen Mary University of London.[2] In 2015 she was awarded the Hooke medal from the British Society for Cell Biology and EMBO membership.[3][4]

Kairbaan Hodivala-Dilke
Alma mater
Known forStudy of Angiogenesis
Scientific career
FieldsCell Biology
InstitutionsBarts and The London School of Medicine and Dentistry

Early life edit

Hodivala-Dilke was born to an Indian Parsi family in South West London.[5]

Education and academic career edit

Hodivala-Dilke's scientific career started as a technical assistant, first at The Jodrell Laboratories, Kew Gardens, and later in the Wellcome Trust funded Malaria Research team at Imperial College, London.[6] Following a BSc in Biology at the University of Southampton, Hodivala-Dilke studied for a PhD in epithelial cell biology with Fiona Watt at Imperial Cancer Research Fund (now part of the Francis Crick Institute) in London.[7] Hodivala-Dilke then moved to The Massachusetts Institute of Technology, for a postdoctoral fellowship with Richard Hynes.[8]

Hodivala-Dilke returned to the UK as an Imperial Cancer Research Fund tenure-track fellow, mentored by Professor Ian Hart, first at St. Thomas’ Hospital and later at Barts Cancer Institute. In 2004 Hodivala-Dilke was awarded tenure and in 2009 became Professor of Angiogenesis. Hodivala-Dilke became Deputy Director of the Barts Cancer Institute in 2012.[2]

Research interests edit

During her studies at The Massachusetts Institute of Technology, Hodivala-Dilke studied adhesion molecules called integrins and her findings support that epidermal α3β1 integrin is required for the prevention of blistering diseases and that αvβ3-integrin is required for blood clotting.[9][10] Subsequently her research interests have been directed to revealing the role that adhesion related molecules have in blood vessel formation (angiogenesis). Her finding that αvβ3-integrin acts as a negative regulator of pathological angiogenesis rather than promoting the growth of new blood vessels, highlighted the requirement for more investigation of how αv-integrin antagonists act in anti-angiogenic treatments.[11]

Studies of a mouse model of Down syndrome have found that 3 copies of some chromosome 21 genes can impede the growth of blood vessels in tumours. These mice provide a system to discover new regulators of blood vessel growth.[12] Recent investigations have increased understanding of the role that stromal focal adhesion kinase (FAK) plays in tumour growth, progression and resistance to chemotherapy.[13][14][15] Hodivala-Dilke's research goal is to study how the tumour microenvironment can control tumour progression and cancer treatment efficacy.[16]

Hodivala-Dilke’s team at Barts Cancer Institute have established the role of stromal focal adhesion kinase (FAK) in chemoresistance. The team have pioneered a novel concept in vascular promotion using low doses of RGD mimetics in enhancing the efficacy of cancer therapy. The team’s overall goal is to discover novel therapeutic vascular targets to modulate stromal control in the control of cancer.[17]

Professional associations and awards edit

References edit

  1. ^ a b "Professor Kairbaan Hodivala-Dilke | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 2019-01-30.
  2. ^ a b "Kairbaan Hodivala-Dilke - Barts Cancer Institute". www.bci.qmul.ac.uk. Retrieved 2019-01-30.
  3. ^ a b "Kairbaan Hodivala-Dilke". EMBO. Retrieved 2019-02-02.
  4. ^ a b "Hooke Medal Winner 2015: Kairbaan Hodivala-Dilke | British Society for Cell Biology". Retrieved 2019-01-31.
  5. ^ "Sophie's child & my cancer research | Professor Kairbaan Hodivala-Dilke | AMSlive". The Global Herald. 26 November 2018. Retrieved 2020-10-11.
  6. ^ Hodivala-Dilke, Kairbaan (2016-04-25). "Kairbaan Hodivala-Dilke". Current Biology. 26 (8): R310–R311. doi:10.1016/j.cub.2016.02.037. ISSN 0960-9822.
  7. ^ "wattlab | alumni". www.wattlab.org. Retrieved 2019-02-02.
  8. ^ "Past lab members | Hynes Lab". hynes-lab.mit.edu. Retrieved 2019-02-02.
  9. ^ Hynes, Richard O.; Kreidberg, Jordan A.; Jaenisch, Rudolf; Hodivala-Dilke, Kairbaan M.; DiPersio, C. Michael (1997-05-05). "α3β1 Integrin Is Required for Normal Development of the Epidermal Basement Membrane". The Journal of Cell Biology. 137 (3): 729–742. doi:10.1083/jcb.137.3.729. ISSN 0021-9525. PMC 2139886. PMID 9151677.
  10. ^ Hodivala-Dilke, Kairbaan M.; McHugh, Kevin P.; Tsakiris, Dimitrios A.; Rayburn, Helen; Crowley, Denise; Ullman-Culleré, Mollie; Ross, F. Patrick; Coller, Barry S.; Teitelbaum, Steven (1999-01-15). "β3-integrin–deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival". Journal of Clinical Investigation. 103 (2): 229–238. doi:10.1172/JCI5487. ISSN 0021-9738. PMC 407888. PMID 9916135.
  11. ^ Hodivala-Dilke, Kairbaan M.; Hynes, Richard O.; Sheppard, Dean; Huang, Xiaozhu; Robinson, Stephen D.; Taverna, Daniela; Lively, Julie C.; Wyder, Lorenza; Reynolds, Louise E. (January 2002). "Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins". Nature Medicine. 8 (1): 27–34. doi:10.1038/nm0102-27. ISSN 1546-170X. PMID 11786903. S2CID 22972632.
  12. ^ Hodivala-Dilke, Kairbaan M.; Hart, Ian R.; Tybulewicz, Victor L. J.; Fisher, Elizabeth M. C.; Adams, Ralf; Imhof, Beat A.; Kermorgant, Stephanie; Turnell, Andrew S.; McCabe, Christopher J. (June 2010). "Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome". Nature. 465 (7299): 813–817. Bibcode:2010Natur.465..813R. doi:10.1038/nature09106. ISSN 1476-4687. PMC 3479956. PMID 20535211.
  13. ^ Hodivala‐Dilke, Kairbaan M.; Parsons, Maddy; Fruttiger, Marcus; Hart, Ian; Kostourou, Vassiliki; Robinson, Stephen; Jadeja, Shalini; Reynolds, Louise E.; Batista, Silvia (2010-12-10). "Endothelial FAK is required for tumour angiogenesis". EMBO Molecular Medicine. 2 (12): 516–528. doi:10.1002/emmm.201000106. ISSN 1757-4676. PMC 3377344. PMID 21154724.
  14. ^ Alexopoulou, Annika N; Lees, Delphine M; Bodrug, Natalia; Lechertier, Tanguy; Fernandez, Isabelle; D'Amico, Gabriela; Dukinfield, Matthew; Batista, Silvia; Tavora, Bernardo (July 2017). "Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead mice". The Journal of Pathology. 242 (3): 358–370. doi:10.1002/path.4911. ISSN 0022-3417. PMC 5518444. PMID 28444899.
  15. ^ Hodivala-Dilke, Kairbaan M.; Gribben, John G.; Perkins, Neil; Hunter, Jill; Ledoux, Adeline; Clear, Andrew; Elia, George; Annika Alexopoulou; Wong, Ping-Pui (October 2014). "Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy". Nature. 514 (7520): 112–116. Bibcode:2014Natur.514..112T. doi:10.1038/nature13541. ISSN 1476-4687. PMC 4533916. PMID 25079333.
  16. ^ Wong, Ping-Pui; Bodrug, Natalia; Hodivala-Dilke, Kairbaan M. (7 November 2016). "Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment". Current Biology. 26 (21): R1161–R1166. doi:10.1016/j.cub.2016.09.043. ISSN 1879-0445. PMID 27825457.
  17. ^ "Professor Kairbaan Hodivala-Dilke". Cancer Research UK Barts Centre. Retrieved 16 September 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kairbaan_Hodivala-Dilke&oldid=1157121991"